Assessment of Prescribing Pattern and Clinical Outcomes among Women with Risk Factor for Preeclampsia
Abstract
Objective(s): Preeclampsia is a pregnancy-specific hypertensive disorder marked by new-onset hypertension and proteinuria after 20 weeks of gestation, and remains a leading cause of maternal and perinatal morbidity and mortality in developing countries. This study was undertaken to assess the clinical profile, drug prescribing pattern, and maternal-fetal outcomes among women with risk factors for preeclampsia attending a tertiary care teaching hospital. Design: A prospective observational study. Intervention(s): Case records of pregnant women with moderate-to-high risk factors for preeclampsia, attending the antenatal clinic of the Department of Obstetrics and Gynaecology, MMIMSR, Mullana, were reviewed over a six-month period. Demographic data, obstetric history, clinical findings, laboratory parameters, and prescribed antihypertensive and supportive medication were recorded on structured case record forms after obtaining informed consent. Main outcome measure(s): Drug prescribing pattern assessed using WHO prescribing indicators, and maternal-foetal outcomes. Results: Of 100 antenatal records screened, 60 women met the risk criteria for preeclampsia. Most patients were 20-30 years of age, and 55% were stratified as high risk and 38.3% as moderate risk on the basis of clinical and laboratory parameters. Labetalol (75%) was the most frequently prescribed antihypertensive, followed by low-dose aspirin/Ecosprin (40%) and magnesium sulphate (15%) for seizure prophylaxis. Supportive therapy included calcium (98.3%), iron (95%), folic acid (16.6%), L-arginine (31.6%), and protein powder (31.6%). About one-third of the women received additional treatment for concomitant illnesses such as diabetes mellitus, hypertension, and thyroid disorders. Conclusion: The drug therapy prescribed to women at risk of preeclampsia at this centre was broadly consistent with WHO and ACOG recommendations, with labetalol as the antihypertensive of choice and low-dose aspirin used for prophylaxis. Standardised treatment protocols, early risk stratification, and continued monitoring are needed to further improve maternal and fetal outcomes.
Keywords: Preeclampsia, Drug Utilization Pattern, Antihypertensive Therapy, Maternal and Fetal Outcomes, Magnesium Sulfate, Biomarkers, Observational Study.
Keywords:
Preeclampsia, Drug Utilization Pattern, Antihypertensive Therapy, Maternal and Fetal Outcomes, Biomarkers, Observational StudyDOI
https://doi.org/10.22270/jddt.v16i8.7940References
1. Hussain S, Yadav S, Khattri S, et al. Assessment of drug prescribing pattern using world health organization indicators in a tertiary care teaching hospital: Indian Journal of Public Health. 2018; 62(2): 156-158. https://doi.org/10.4103/ijph.IJPH_429_16 PMid:29923544
2. Jain S, Upadhyaya P, Moghe V, et al. A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines: Perspective in Clinical Research. 2015; 6(2): 86-90. https://doi.org/10.4103/2229-3485.154005 PMid:25878953 PMCid:PMC4394586
3. American College Of Obstetrics and Gynaecologist, Task force on hypertension in pregnancy. Hypertension in pregnancy. Report on American College of Obstetrics and Gynaecologist’ Task force on hypertension in pregnancy. Obstetrics Gynecology. 2013; 122:1122.
4. Lenfant C,working group report on high blood pressure in pregnancy: Journal Clin Hypertens (Greenwich). 2001.
5. Wagner LK, M.D, et al. Diagnosis and Management of preeclampsia: American Family Physician. 2004; 70(12): 2317-2324.
6. Henderson JT, Whitlock EP, O’Connor, et al. Low-dose aspirin for prevention of morbidity from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 160:695. https://doi.org/10.7326/M13-2844 PMid:24711050
7. Rana S, Lemoine E, Granger JP, et al. Preeclampsia pathophysiology, challenges and perspectives: Circulation Research. 2019; 124:1094-1112. https://doi.org/10.1161/CIRCRESAHA.118.313276 PMid:30920918 PMCid:PMC12042644
8. Odegard RA, Austgulen R, et al. Preeclampsia and fetal growth: Obstetrics and Gynecology. 2000; 96(6): 950-955. https://doi.org/10.1097/00006250-200012000-00016 PMid:11084184
9. American College Of Obstetrics and Gynaecologist. ACOG committee opinion number 743: Committee on obstetrics practice society for maternal-foetal medicine. Obstetrics and Gynaecology. 2018; 132(1):e44-e52. https://doi.org/10.1097/AOG.0000000000002708 PMid:29939940
10. Hladunewich M, Karumanchi SA, Lafayette R, et al. Pathophysiology of the clinical manifestations of preeclampsia: Clin Journal Am Soc Nephrol. 2007; 2(3):543-549. https://doi.org/10.2215/CJN.03761106 PMid:17699462
11. Lunde PK, Baksaas I, et al. Epidemiology of drug utilization basic concepts and methodology: Acta Med Scand Suppl. 1988; 721:7-11. https://doi.org/10.1111/j.0954-6820.1987.tb05371.x PMid:3281414
12. Strom BL, Pharmacoepidemiology. Fourth ed: John Wiley & Sons, Ltd 2005.
13. Costa J, Rosa MM, Ferreira JJ, Sampaio C, et al. Cardiac effects of acute poisoning with tricyclic antide-pressants: systematic review of the literature. Part I. Rev Port Cardiol. 2001; 20:671-678.
14. Strom BL, Melmon KL, Miettinen OS, et al. Postmarketing studies of drug efficacy: Arch Intern Med. 1985; 145:1791-1794. https://doi.org/10.1001/archinte.1985.00360100051005 PMid:3899034
15. Andersen M, Is it possible to measure prescribing quality using only prescription data? Basic Clin Pharmacol Toxicol. 2006; 98:314-319. https://doi.org/10.1111/j.1742-7843.2006.pto_411.x PMid:16611208
16. Wettermark B, Hammar N, MichaelFored C, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepide-miological research: Pharmacoepidemiological Drug Safety. 2007; 16:726-735. https://doi.org/10.1002/pds.1294 PMid:16897791
17. Naqvi SH, Dunkle LM, Timmerman KJ, Reichley RM, Stanley DL, O’Connor D, et al. Antibiotic usage in a pediatric medical center: Journal of the American Medical Association.1979; 242:1981-1984. https://doi.org/10.1001/jama.1979.03300180025025 PMid:480644
18. Scheckler WE, Bennett JV, et al. Antibiotic usage in seven community hospitals: Journal of the American Medical Association. 1970; 213:264-267. https://doi.org/10.1001/jama.1970.03170280024004 PMid:5467892
19. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M, et al. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study: The Cardiovascular Health Study Collaborative Research Group, Journal Clin Epidemiology .1992; 45:683-692. https://doi.org/10.1016/0895-4356(92)90143-B PMid:1607909
20. Avorn J, Soumerai SB, et al. Improving drug-therapy decisions through educational outreach-A randomized controlled trial of academically based ‘detailing’: N Engl Journal Med. 1983; 308:1457-1463. https://doi.org/10.1056/NEJM198306163082406 PMid:6406886
21. Ray WA, Schaffner W, Federspiel CF, et al. Persistence of improvement in antibiotic prescribing in office practice: Journal of the American Medical Association. 1985; 253:1774-1776. https://doi.org/10.1001/jama.1985.03350360100028 PMid:3974058
22. Schaffner W, Ray WA, Federspiel CF, Miller WO, et al. Improving antibiotic prescribing in office practice: Journal of the American Medical Association. 1983; 250: 1728-1732. https://doi.org/10.1001/jama.1983.03340130046031 PMid:6350633
23. Chesley L, Hypertensive Disorders in Pregnancy: Elsevier. 2015; 4:221-231.
24. Myatt L, Clifton RG, Roberts JM, et al. First-trimester prediction of preeclampsia in nulliparous women at low risk: Obstetrics & Gynecology. 2012; 119(6):1234--1242. https://doi.org/10.1097/AOG.0b013e3182571669 PMid:22617589 PMCid:PMC3360523
25. Myatt L, Roberts JM, et al. Preeclampsia: Syndrome or Disease: Current Hypertension Reports.2015; 17: 83. https://doi.org/10.1007/s11906-015-0595-4 PMid:26362531
26. Ghulmiyyah L, Sibai B,et al. Maternal Mortality From Preeclampsia/Eclampsia: Seminars in Perinatology.2012; 36(1): 56-59. https://doi.org/10.1053/j.semperi.2011.09.011 PMid:22280867
27. Say L, Chou D, Gemmill A, et al. Global causes of maternal death:- a WHO systematic analysis: The Lancet Global Health. 2014; 2(6): e323--e333. https://doi.org/10.1016/S2214-109X(14)70227-X PMid:25103301 PMCid:PMC11635789
28. Uzan J, Carbonnel M, Piconne O, Asmar R, et al. Pre-eclampsia: pathophysiology, diagnosis and management: Vascular Health and Risk Management. 2011; 7: 467--474. https://doi.org/10.2147/VHRM.S20181 PMid:21822394 PMCid:PMC3148420
29. Meads CA, Cnossen JS, Meher S, et al. Methods of prediction and prevention of preeclampsia: systematic reviews of accuracy and effectiveness literature with economic modeling: Health Technol Assess. 2008; 12: 1--270. https://doi.org/10.3310/hta12060
30. Osmond C, Kajantie E, Forsén TJ, Eriksson JG, Barker DJ, et al. Infant growth and stroke in adult life: the Helsinki Birth Cohort Study. 2007; 38:264--270. https://doi.org/10.1161/01.STR.0000254471.72186.03 PMid:17218608
31. Eriksson JG, Forsén T, Tuomilheto J, Osmond C, Barker DJ, et al. Early growth and coronary heart disease in later life, longitudinal study: British Medical Journal. 2001; 322:949--953. https://doi.org/10.1136/bmj.322.7292.949 PMid:11312225 PMCid:PMC31033
32. Barker DJ, Martyn CN, Osmond C, Hales CN, et al. Growth in utero and serum cholesterol concentrations in adult life: British Medical Journal. 1993; 307:1524--1527. https://doi.org/10.1136/bmj.307.6918.1524 PMid:8274921 PMCid:PMC1679540
33. Warrington JP, George EM, Palei AC, Spradley FT, et al. Recent advances in the understanding of the pathophysiology of preeclampsia: Hypertension. 2013; 62(4):666-673. https://doi.org/10.1161/HYPERTENSIONAHA.113.00588 PMid:23897068 PMCid:PMC3856636
34. Reddy A, Suri S, Sargent IL, Redman CWG, Muttukrishna S, et al. Maternal circulating levels of activin A, inhibin A, sFlt-1 and endoglin at parturition in normal pregnancy and preeclampsia: PLoSONE.2009;4(2): e4453. https://doi.org/10.1371/journal.pone.0004453 PMid:19412349 PMCid:PMC2675175
35. Portelli M, Baro B, et al. Clinical Presentation of Preeclampsia and the Diagnostic Value of Proteins and Their Methylation Products as Biomarkers in Pregnant Women with Preeclampsia and Their Newborns: Journal of Pregnancy. 2018; 1-23. https://doi.org/10.1155/2018/2632637 PMid:30050697 PMCid:PMC6046127
36. Wagner LK, Diagnosis and management of preeclampsia: American Family Physician. 2004; 70(12): 2317--2324.
37. Guimarães filho HA, Araujo júnior E, Nardozza LM et-al. Ultrasound assessment of the fetal biophysical profile: Eur Journal Radiol. 2008; 66 (1): 122-126. https://doi.org/10.1016/j.ejrad.2007.05.011 PMid:17587525
38. Robinson CJ, Johnson DD, et al. Soluble endoglin as a second-trimester marker for preeclampsia: Am Journal Obstet Gynecol.2007; 197(2):174:e1-5. https://doi.org/10.1016/j.ajog.2007.03.058 PMid:17689640
39. Thadhani R, Mutter WP, Wolf M, et al. First trimester placental growth factor and soluble Fms-like tyrosine kinase 1 and risk for preeclampsia: Journal Clin Endocrinol Metabol. 2004; 89:770--775. https://doi.org/10.1210/jc.2003-031244 PMid:14764795
40. Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, et al. Urinary placental growth factor and risk of preeclampsia: Journal of the American Medical Association. 2005; 293:77-85. https://doi.org/10.1001/jama.293.1.77 PMid:15632339
41. Hagmann H, Thadhani R, Benzing T, Karumanchi S A, et al. The Promise of Angiogenic Markers for the Early Diagnosis and Prediction of Preeclampsia: journal Clin Chem. 2012; 58:837-845. https://doi.org/10.1373/clinchem.2011.169094 PMid:22431894
42. Levine RJ, Maynard SE, Qian C, Lim KH, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia: N Engl Journal Med. 2004; 350:672-683. https://doi.org/10.1056/NEJMoa031884 PMid:14764923 PMCid:PMC12042644
43. Karumanchi SA, Lindheimer MD, et al. Preeclampsia pathogenesis: ‘Triple a rating’ autoantibodies and anti-angiogenic factors Hypertension. 2008; 51:991-992. https://doi.org/10.1161/HYPERTENSIONAHA.107.100735 PMid:18259040
44. Wolf M, Shah A, Lam C, et al. Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies: Am Journal Obstet Gynecol. 2005; 193:16--22. https://doi.org/10.1016/j.ajog.2005.03.016 PMid:16021053
45. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia: Journal Clin Investig. 2003; 111:649--658. https://doi.org/10.1172/JCI17189 PMid:12618519 PMCid:PMC151901
46. Mutter WP, Karumanchi SA, et al. Molecular mechanisms of preeclampsia: Microvas Res. 2008; 75:1-8. https://doi.org/10.1016/j.mvr.2007.04.009 PMid:17553534 PMCid:PMC2241748
47. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia: Nature Med. 2006; 12:642--649. https://doi.org/10.1038/nm1429 PMid:16751767 PMCid:PMC12042644
48. Rana S, Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia: Hypertension. 2007; 50:137--142. https://doi.org/10.1161/HYPERTENSIONAHA.107.087700 PMid:17515455
49. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, et al. Inflammation and angiotensin II: Intl Journal of Biochem and Cell Biol. 2003; 35:881-900. https://doi.org/10.1016/S1357-2725(02)00271-6 PMid:12676174
50. Fujimoto Y, Sasaki T, Tsuchida A, Chayama K, et al. Angiotensin II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotensin II type 1 receptor antagonist: FEBS Letters. 2001; 495:197-200. https://doi.org/10.1016/S0014-5793(01)02377-8 PMid:11334891
51. Paul M, Mehr AP, Kreutz R, et al. Physiology of local renin angiotensin systems: Physiol Reviews. 2006; 86:747-803. https://doi.org/10.1152/physrev.00036.2005 PMid:16816138
52. Redman CW, Sargent IL, et al. Latest advances in understanding preeclampsia: Science. 2005; 308:1592-1594. https://doi.org/10.1126/science.1111726 PMid:15947178 PMCid:PMC12042644
53. Hubel CA, Wallukat G, Wolf M, Herse F, Rajakumar A, et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsia :Hypertension. 2007; 49:612-617. https://doi.org/10.1161/01.HYP.0000256565.20983.d4 PMid:17210828
54. Irani RA, Zhang Y, Blackwell SC, et al. The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia: Journal of Exp Med. 2009; 206:2809-2822. https://doi.org/10.1084/jem.20090872 PMid:19887397 PMCid:PMC2806612
55. Nicolaides KH, Bindra R, Turan OM, et al. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound: Ultrasound Obstet Gynecol. 2006; 27:13-17. https://doi.org/10.1002/uog.2686 PMid:16374755
56. Burger O, Pick E, Zwickel J, et al. Placental protein 13 (PP-13): Effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies Placenta: British Medical Journal. 2004; 25:608-622. https://doi.org/10.1016/j.placenta.2003.12.009 PMid:15193867
57. Chaftez I, Kuhnreich I, Sammar M, et al. First trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction: Am Journal Obstet Gynecol. 2007; 197:35(e1)-35(e7). https://doi.org/10.1016/j.ajog.2007.02.025 PMid:17618748
58. Bersinger NA, Smarason AK, Muttukrishna S, et al. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A, and soluble E-selectin: Hypertens Pregnancy. 2003; 22:45-55. https://doi.org/10.1081/PRG-120016794 PMid:12648442
59. Yaron Y, Heifetz S, Ochshorn Y, Lehavi O, et al. Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome: Prenat Diagn. 2002; 22:778-782. https://doi.org/10.1002/pd.407 PMid:12224070
60. Smith GC, Stenhouse EJ, Crossley JA, et al. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth: Journal Clin Endocrinol Metabol. 2002; 87:1762--1767. https://doi.org/10.1210/jcem.87.4.8430 PMid:11932314
61. Canini S, Prefumo F, Pastorino D, et al. Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A: Fertil and Steril. 2008; 89: 174--178. https://doi.org/10.1016/j.fertnstert.2007.02.024 PMid:17509577
62. Preiss J, Handler P, et al. Enzymatic synthesis of nicotinamide mononucleotide: Journal Biol Chem. 1957; 225:759-770. https://doi.org/10.1016/S0021-9258(18)64875-6 PMid:13416279
63. Frasshauer M, Bluher M, Stumvoll M, Tonessen P, Stepan H, et al. Differential regulation of visfatin and adiponectin in pregnancies with normal and abnormal placental function: Clin Endocrinol. 2007; 66:434-439. https://doi.org/10.1111/j.1365-2265.2007.02751.x PMid:17302880
64. Hu W, Wang Z, Wang H, Huang H, et al. Serum visfatin levels in late pregnancy and pre-eclampsia: Acta Obstet Gynaecol Scand. 2008; 87:413-418. https://doi.org/10.1080/00016340801976012 PMid:18382866
65. Luisi S, Florio P, Reis FM, Petraglia F, et al. Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy: Hum Reprod Update. 2005; 11:123--135. https://doi.org/10.1093/humupd/dmh057 PMid:15618291
66. Muttukrishna S, Hyett J, Paine M, et al. Uterine vein and maternal urinary levels of activin A and inhibin A in pre-eclampsia patients: Clin Endocrinol (Oxf). 2006; 64:469-473. https://doi.org/10.1111/j.1365-2265.2006.02476.x PMid:16584522
67. Mandang S, Maneulpillai U, Wallace EM, et al. Oxidative stress increases placental and endothelial cell activin A secretion: Journal Endocrinol. 2007; 192:485-493. https://doi.org/10.1677/JOE-06-0061 PMid:17332518
68. Kim SY, Ryu HM, Yang JH, et al. Maternal serum and amniotic fluid inhibin A levels in women who subsequently develop severe preeclampsia: Journal Korean Med Science. 2006; 21:452--456. https://doi.org/10.3346/jkms.2006.21.3.452 PMid:16778388 PMCid:PMC2729950
69. Davidson EJ, Riley SC, Roberts SA, et al. Maternal serum activin, inhibin, human chorionic gonadotrophin and alpha-fetoprotein as second trimester predictors of pre-eclampsia: British Journal Obstet Gynaecol. 2003; 110:46-52. https://doi.org/10.1016/S1470-0328(02)02937-3
70. Roes EM, Gaytant MA, Thomas CM, et al. First trimester inhibin-A concentrations and later development of preeclampsia: Acta Obstetricia Gynecologica Scandinavica. 2004; 83:117. https://doi.org/10.1080/j.1600-0412.2004.00140.x PMid:14758802
71. Dukes MNG. Introduction. In: Drug Utilization Studies: Methods and Uses. Edited by Dukes MNG. 1992. WHO Regional Publications, European Series, No. 45, 1-4.
72. Lee D, Bergman U, et al. Studies of Drug Utilization: Pharmaco-epidemiology: West Sussex: John Wiley & Sons, Ltd.1994; 2: 379-393.
73. Erwin WG. The Definition of Drug Utilization Review: Statement of Issues: Clinical Pharmacology & Therapeutics. 1991; 50(5, part 2, November): 596-599. https://doi.org/10.1038/clpt.1991.188 PMid:1934874
74. Sunol R, Abello C, Cels IC, et al. Studies in Utilization of Drugs: a Review of Different Methods: Quality Assurance in Health Care. 1991; 3(1):63-72. https://doi.org/10.1093/intqhc/3.1.63 PMid:1873531
75. Griffiths K, McDevitt DG, Andrew M, et al. Therapeutic Traditions in Northern Ireland, Norway and Sweden- I. Diabetes: European Journal of Clinical Pharmacology. 1986; 30:513-519. https://doi.org/10.1007/BF00542408 PMid:3530780
76. Andrew M, Griffiths K, McDevitt DG, et al. Therapeutic Traditions in Northern Ireland, Norway and Sweden- II. Hypertension: European Journal of Clinical Pharmacology. 1986; 30:521-525. https://doi.org/10.1007/BF00542409 PMid:3758139
77. Haaijer FM, De Jong-Van den Berg LTW, et al. Drug Utilization Studies and Drug Monitoring in the Netherlands: Annali dell’ Istituto Superiore di Sanita. 1991; 27(2):217-224.
78. National Institute for Health and Care Excellence (NICE) NICE CG 107. Manchester, UK: National Institute for Health and Clinical Excellence; 2010. [Accessed February 5, 2015]. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy.
79. Lancet C, et al. low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women CLASP (Collaborative Low-dose Aspirin Study in Pregnancy): Collaborative Group. 1994; 343(8898):619--629. https://doi.org/10.1016/S0140-6736(94)92633-6
80. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L,et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems: Cochrane Database System Revised. 2014;6:CD001059. https://doi.org/10.1002/14651858.CD001059.pub4
81. Myers JE, Baker PN, et al. Hypertensive diseases and eclampsia: Current Opinion Obstetrics Gynecol. 2002; 14(2):119--125. https://doi.org/10.1097/00001703-200204000-00004 PMid:11914688
82. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy: American Journal of Obstetrics Gynecology .2000; 183: S1-22. https://doi.org/10.1067/mob.2000.107928 PMid:10920299
83. Abalos E, Duley L, Steyn D,et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy: Cochrane Database System Revised. 2001 ;2:CD002252. https://doi.org/10.1002/14651858.CD002252
84. American College Of Obstetrics and Gynaecologist Committee on Obstetric Practice: ACOG practice bulletin, Diagnosis and management of preeclampsia and eclampsia: ACOG Obstet Gynecol. 3002; 99:159-167. https://doi.org/10.1016/S0029-7844(01)01747-1 PMid:16175681
85. Koopmans CM, Bijlenga D, Groen H, et al. HYPITAT study group Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks’ gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009; 374(9694):979--988. https://doi.org/10.1016/S0140-6736(09)60736-4 PMid:19656558
86. Duley L, Meher S, Abalos E, et al. Management of pre-eclampsia: British Medical Journal. 2006; 332(7539): 463--468. https://doi.org/10.1136/bmj.332.7539.463 PMid:16497761 PMCid:PMC1382544
87. Pryde PG, Mittendorf R, et al. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose: Obstetrics & Gynecologist. 2009;114:669--673. https://doi.org/10.1097/AOG.0b013e3181b43b0e PMid:19701048
88. National Institute for Health and Care Excellence (NICE) Severe Hypertension, Severe Pre-Eclampsia and Eclampsia in Critical Care---Nice Clinical Guideline. Royal College of Obstetricians and Gynaecologists; London, UK: 2015.
89. Peres G, Mariana M, Cairrao E, et al. Pre-Eclampsia and Eclampsia: An Update on the Pharmacological Treatment Applied in Portugal: Journal of Cardiovascular Development and Disease. 2018 Mar; 5(1): 3. https://doi.org/10.3390/jcdd5010003 PMid:29367581 PMCid:PMC5872351
90. Bouet PE, Brun S, Madar H, Baisson AL, Courtay V, Lasocki S, et al. Implementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infants: Scientific Report. 2015; 5:14732. https://doi.org/10.1038/srep14732 PMid:26415713 PMCid:PMC4586759
91. American College of Obstetricians and Gynecologists. Low- dose aspirin use during pregnancy Committee Opinion. Number-743. 2018.
92. WHO. In: Who Recommendations for Prevention and Treatment of Pre-Eclampsia and Eclampsia. 2013:7: 8--27.
93. Roberge S, Villa P, Nicolaides K, Giguere Y, Vainio M, Bakthi , et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: Fetal Diagnosis & Therapy 2012; 31:141--146. https://doi.org/10.1159/000336662 PMid:22441437
94. Mol BW, Roberts CT, Thangaratinam S, Magee LA, et al. Pre-eclampsia: Lancet. 2015; 387:999--1011. https://doi.org/10.1016/S0140-6736(15)00070-7 PMid:26342729
95. Tong S, Mol BW, Walker SP, et al. Preventing preeclampsia with aspirin: American Journal of Obstetrics & Gynecologist. 2017; 216:95--97. https://doi.org/10.1016/j.ajog.2016.12.003 PMid:28148451
96. Meher S, Duley L, Hunter K, Askie L, et al. Antiplatelet therapy before or after 16 weeks’ gestation for preventing preeclampsia: American Journal of Obstetrics & Gynecologist. 2017; 216:121--128. https://doi.org/10.1016/j.ajog.2016.10.016 PMid:27810551
97. Chandiraman M, Shennan Ah, et al. Modern management of postpartum hypertension: Trends in Urology, Gynaecology & Sexual Health. 2007:12: 37-42. https://doi.org/10.1002/tre.40
98. Fred A , Louise C , Fergus P, et al. Risk factors and effective management of preeclampsia: Integr Blood Pressure Control. 2015; 8: 7--12. https://doi.org/10.2147/IBPC.S50641 PMid:25767405 PMCid:PMC4354613
99. Podymow T, August P, et al. Antihypertensive drugs in pregnancy: Semin Nephrol Journal. 2011; 31(1):70--85. https://doi.org/10.1016/j.semnephrol.2010.10.007 PMid:21266266
100. Lowe SA, Brown MA, Dekker GA, Gatt S, McLintock CK, McMahonLP,etal. Guidelines for the management of hypertensive disorders of pregnancy: Australian & New Zealand Journal of Obstetrics Gynaecology. 2009; 49(3):242-246. https://doi.org/10.1111/j.1479-828X.2009.01003.x PMid:19566552
Published
Abstract Display: 62 
PDF Downloads: 61 PDF Downloads: 9 How to Cite
Issue
Section
Copyright (c) 2026 Shaivi Parashar , Sumeet Gupta , Vaishali Verma , Ankit Goel, Vikas Sharma , Renu Sharma, Rahul Kaushik , Krishan Kumar Verma
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.